SWEDISH ORPHAN BIOVIT.SK1
SWEDISH ORPHAN BIOVIT.SK1/ SE0000872095 /
B6E
16.10.2024 19:27:29
|
Zm.
+0,020
|
Wolumen |
Bid19:27:29 |
Ask19:27:29 |
Kapitalizacja Rynkowa |
St. dywidendy |
Wskaźnik C/Z |
25,860EUR
|
+0,08%
|
- Obrót: - |
25,860Wolumen Bid: - |
26,180Wolumen Ask: - |
9,29 mldEUR |
- |
- |
Opis działalności
Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
Zarząd & Rada nadzorcza
CEO |
Guido Oelkers |
Zarząd |
Henrik Stenqvist, Lydia Abad-Franch, Duane H. Barnes, Lena Bjurner, Sofiane Fahmy, Torbjörn Hallberg, Mahmood Ladha, Norbert Oppitz, Daniel Rankin, Armin Reininger, Christine Wesström |
Rada nadzorcza |
Annette Clancy, Christophe Bourdon, Helena Saxon, Staffan Schüberg, Katy Mazibuko, Mats Lek, Anders Ullman, Filippa Stenberg |
Dane firmy
Nazwa: |
Swedish Orphan Biovitrum AB |
Adres: |
Tomtebodavägen 23A,Solna 112 76 |
Telefon: |
+46-8-697-2000 |
Fax: |
- |
E-mail: |
-
|
Internet: |
www.sobi.com |
Przemysł: |
Biotechnologia |
Sektor: |
Biotechnologia |
Podsektor: |
Biotechnologia |
Koniec roku finansowego: |
31.12 |
Free float: |
42,16% |
Data IPO: |
- |
Główni akcjonariusze
Inne |
|
38,50% |
Investor Aktiebolag |
|
34,70% |
Morgan Stanley Smith Barney Llc, W9 |
|
9,89% |
Fjärde AP-fonden |
|
5,93% |
State Street Bank And Trust Co, W9 |
|
4,27% |
Jp Morgan Chase Bank Na |
|
3,51% |
Northern Trust Company, London Branch |
|
3,20% |